ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2019

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway.

Pijian Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.